This has been a while in the making, so I'm glad to see this come through, especially before winter in North America. Definite wildcard that's swung in our favour.
A few things come to mind: - PRODUCT: While the focus on COVID19 has definitely waned since pandemic levels, the resurgence given new strain and political interest on vaccines may see a modest boost to sales. Especially if we can mobilise on distribution and production before flu season. - CAPABILITY: It's another tick for Doug (and team) since joining. If we continue building out a suite of POC solutions, it definitely gives confidence knowing that we've been able to successfully navigate the FDA process, which can often make or break a company. - COMMERCIALISATION: I'm keen to see how LDX management navigate the commercialisation of both ViraDx and FebriDx, while balancing resources to existing commercial service arrangements. They've had to significantly restructure their business in the past year, including centralising facilities to the one Carlsbad facility, so I look forward to reading the quarterlys. As I mentioned in another post, I'm more confident of management who've had to gut a company, to know the cost of a sustainable dollar.
DYOR. AIMHO. GLTAH.
LDX Price at posting:
10.3¢ Sentiment: Buy Disclosure: Held
